Lisocabtagene Maraleucel
‘A true travesty’: Despite new data and guidance, people with HIV still lack access to CAR-T
Individuals living with HIV historically have been at higher risk for non-Hodgkin lymphoma.
CAR T cells improve quality of life for majority of recipients
Patients with hematologic malignancies reported significant improvement in quality of life after receiving chimeric antigen receptor T cells, results from a longitudinal study in Blood Advances showed.
Breyanzi study meets complete response endpoint for leukemia, lymphoma subgroup
A phase 1/phase 2 trial of lisocabtagene maraleucel for adults with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma met its primary endpoint, according to the agent’s manufacturer.
Efficacy, safety data support use of lisocabtagene maraleucel at community sites
NEW ORLEANS — Lisocabtagene maraleucel can be administered safely in the community setting to patients relapsed or refractory large B-cell lymphoma, according to phase 2 study results.
FDA expands Breyanzi approval for relapsed or refractory large B-cell lymphoma
The FDA approved lisocabtagene maraleucel for treatment of adults with relapsed or refractory large B-cell lymphoma after one prior therapy.
CAR-T demonstrates efficacy as second-line therapy for transplant-ineligible lymphoma
CHICAGO — Second-line therapy with lisocabtagene maraleucel induced initial complete remission among more than half of patients with relapsed or refractory transplant-ineligible large B-cell lymphoma, results from a phase 2 trial showed.
FDA grants priority review to Breyanzi for second-line treatment of large B-cell lymphoma
The FDA granted priority review to lisocabtagene maraleucel as second-line treatment of adults with relapsed or refractory large B-cell lymphoma.
Liso-cel significantly improves outcomes in second-line DLBCL
Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with relapsed or refractory large B-cell lymphoma, according to study results presented at ASH Annual Meeting and Exposition.
Treatment landscape promising for relapsed or refractory diffuse large B-cell lymphoma
Nearly 30,000 new cases of diffuse large B-cell lymphoma are diagnosed annually in the United States.
CAR-T extends EFS as second-line therapy for advanced B-cell lymphoma, topline data show
Lisocabtagene maraleucel extended EFS and PFS compared with high-dose chemotherapy and hematopoietic stem cell transplant for relapsed or refractory large B-cell lymphoma, according to topline data released by the agent’s manufacturer.